Holen Sie sich die Stockscreener-App
6.71
1.76%
-0.12
Handel nachbörslich:
6.71
Schlusskurs vom Vortag:
$6.83
Offen:
$6.78
24-Stunden-Volumen:
2.75M
Relative Volume:
1.03
Marktkapitalisierung:
$2.06B
Einnahmen:
$493.67M
Nettoeinkommen (Verlust:
$-104.69M
KGV:
-19.74
EPS:
-0.34
Netto-Cashflow:
$-31.51M
1W Leistung:
-0.15%
1M Leistung:
-25.49%
6M Leistung:
-44.13%
1J Leistung:
-36.76%
1-Tages-Spanne:
$6.66
$6.915
1-Wochen-Bereich:
$6.63
$6.945
52-Wochen-Spanne:
$6.20
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Firmenname
Amicus Therapeutics Inc
Sektor
Branche
Telefon
(609) 662-2000
Adresse
47 HULFISH STREET, PRINCETON, NJ
Vergleichen Sie FOLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.71 | 2.06B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Eingeleitet | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2024-05-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Fortgesetzt | Goldman | Neutral |
| 2022-01-14 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-27 | Eingeleitet | Needham | Hold |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2021-02-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-02-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-06-05 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Eingeleitet | Janney | Buy |
| 2019-01-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Eingeleitet | Citigroup | Neutral |
| 2018-08-17 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
| 2017-09-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-08-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-01-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Eingeleitet | BofA/Merrill | Buy |
| 2016-04-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2016-04-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2015-09-16 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 | FOLD Stock News - GuruFocus
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 - GlobeNewswire
Jump Financial LLC Sells 105,944 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Pompe Disease Therapeutic Market Projected To Witness - openPR.com
Granite Investment Partners LLC Purchases 166,657 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Renaissance Technologies LLC Has $19.86 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
4 Healthcare Stocks to Buy as the Sector Faces Government Heat - Yahoo Finance
(FOLD) Proactive Strategies - news.stocktradersdaily.com
Pompe Disease Treatment Market New Product Development & Latest Trends | Sanofi,Amicus Therapeutics,Genzym - openPR.com
Enzyme Replacement Therapy Market Is Booming Worldwide - openPR.com
Amicus Therapeutics (NASDAQ:FOLD) Shares Down 6.3%Should You Sell? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Sets New 52-Week LowHere's What Happened - MarketBeat
ExodusPoint Capital Management LP Sells 537,938 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Norges Bank Invests $29.03 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Is Amicus Therapeutics, Inc. (FOLD) the Best Low Priced Growth Stock To Invest In? - Insider Monkey
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
Massachusetts Financial Services Co. MA Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Fabry Disease Treatment Market Opportunity and Forecast Report 2025-2034 Featuring Amicus Therapeutics, Avrobio, Freeline, Idorsia, ISU Abxis, JCR, Novartis, Pfizer, Protalix, Sanofi, Takeda, Viatris - Yahoo Finance
Analysts Expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) To Breakeven Soon - Yahoo Finance
JPMorgan Chase & Co. Cuts Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics stock hits 52-week low at $6.99 By Investing.com - Investing.com South Africa
Vanguard Group Inc. Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics stock hits 52-week low at $6.99 - Investing.com
Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires? - Insider Monkey
Research Analysts Issue Forecasts for FOLD Q1 Earnings - MarketBeat
Trexquant Investment LP Acquires 486,827 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
AMICUS STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. - Bluefield Daily Telegraph
AMICUS STOCKHOLDER ALERT: Kaskela Law LLC Announces - GlobeNewswire
Old West Investment Management LLC Raises Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for FOLD - MarketBeat
Pictet Asset Management Holding SA Sells 110,241 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
KLP Kapitalforvaltning AS Purchases New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 52-Week LowHere's What Happened - MarketBeat
Wellington Management Group LLP Buys 4,497,950 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.75 - MarketBeat
Relative Strength Alert For Amicus Therapeutics - Nasdaq
Amicus Therapeutics stock hits 52-week low at $8.09 - Investing.com
Finanzdaten der Amicus Therapeutics Inc-Aktie (FOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):